KEMPHARM INC. DL-0001
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more
Market Cap & Net Worth: KEMPHARM INC. DL-0001 (1GDA)
KEMPHARM INC. DL-0001 (F:1GDA) has a market capitalization of $499.87 Million (€486.97 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #11136 globally and #1196 in its home market, demonstrating a 16.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying KEMPHARM INC. DL-0001's stock price €8.65 by its total outstanding shares 56297535 (56.30 Million).
KEMPHARM INC. DL-0001 Market Cap History: 2015 to 2026
KEMPHARM INC. DL-0001's market capitalization history from 2015 to 2026. Data shows change from $1.00 Billion to $488.31 Million (-5.20% CAGR).
KEMPHARM INC. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how KEMPHARM INC. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 1GDA by Market Capitalization
Companies near KEMPHARM INC. DL-0001 in the global market cap rankings as of March 18, 2026.
Key companies related to KEMPHARM INC. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
KEMPHARM INC. DL-0001 Historical Marketcap From 2015 to 2026
Between 2015 and today, KEMPHARM INC. DL-0001's market cap moved from $1.00 Billion to $ 488.31 Million, with a yearly change of -5.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €488.31 Million | +14.19% |
| 2025 | €427.63 Million | -6.92% |
| 2024 | €459.41 Million | +48.60% |
| 2023 | €309.17 Million | +27.53% |
| 2022 | €242.42 Million | -46.56% |
| 2021 | €453.63 Million | +953.69% |
| 2020 | €43.05 Million | +49.60% |
| 2019 | €28.78 Million | -68.28% |
| 2018 | €90.73 Million | -53.34% |
| 2017 | €194.46 Million | +20.01% |
| 2016 | €162.04 Million | -83.81% |
| 2015 | €1.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of KEMPHARM INC. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $499.87 Million USD |
| MoneyControl | $499.87 Million USD |
| MarketWatch | $499.87 Million USD |
| marketcap.company | $499.87 Million USD |
| Reuters | $499.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.